Screener
ImmunityBio, Inc. IBRX Operating Lease Liability Payments Due
Operating Lease Liability Payments Due at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Years Ending December 31: | Operating Leases | Finance Leases | Total |
|---|---|---|---|
| 2028 | 11,349 | 79 | 11,428 |
| 2029 | 10,221 | 79 | 10,300 |
| 2030 | 7,837 | 34 | 7,871 |
| 2031 | 1,523 | — | 1,523 |
| Thereafter | 453 | — | 453 |
| Total future minimum lease payments | 51,269 | 330 | 51,599 |
| Less: Interest | 10,496 | 64 | 10,560 |
| Present value of lease liabilities | $40,773 | $266 | $41,039 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s operating lease liability payments due?
- ImmunityBio, Inc. (IBRX) reported operating lease liability payments due of $51.27M in Q1 2026.
- How has ImmunityBio, Inc.'s operating lease liability payments due changed year-over-year?
- ImmunityBio, Inc.'s operating lease liability payments due decreased by 2.7% year-over-year, from $52.68M to $51.27M.
- What does operating lease liability payments due mean?
- This represents the total future cash outflows required to satisfy operating lease agreements. It reflects the company's reliance on leased assets rather than owned assets to conduct business operations. Monitoring this helps evaluate the company's operational leverage and fixed cost structure.
Ask your AI about ImmunityBio, Inc.'s operating lease liability payments due.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude